<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085678</url>
  </required_header>
  <id_info>
    <org_study_id>G0F9119N</org_study_id>
    <nct_id>NCT05085678</nct_id>
  </id_info>
  <brief_title>Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy</brief_title>
  <official_title>Development and Evaluation of a PROMs-based Interactive Programme as a Supporting Tool for Breast Cancer Patients Using Adjuvant Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of an online tool, based on patient&#xD;
      reported outcomes (Co'moon), on the quality of life of breast cancer patients on adjuvant&#xD;
      endocrine therapy in the University Hospital Leuven.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project aims to develop and evaluate an online programme to support patients with breast&#xD;
      cancer on adjuvant endocrine therapy in the University Hospital Leuven. The tool &quot;Co'moon&quot;&#xD;
      has been developed in the first phase of the project and secondly refine in a pilot study. In&#xD;
      the third phase a randomised controlled study investigates the effect of Co'moon in&#xD;
      comparison with the standard of care in the University Hospital Leuven. Hereby focussing on&#xD;
      the improvement of self-efficacy en quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial with convenience sampling</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of Life - FACT-ES - B5 - H18</measure>
    <time_frame>monthly after two months of AET; up to 3 months</time_frame>
    <description>Total score of Functional Assessment of Chronic Illness Therapy system of Quality of Life questionnaires of endocrine symptoms (FACT-ES) combined with additional questions B5 and H18. A validated questionnaire with a 5-point Likert scale and a total score of 180 (high QoL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in self-efficacy</measure>
    <time_frame>month 3 and 6 or 7 after the start with AET</time_frame>
    <description>patient reported impact on the side effects of AET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapy adherence</measure>
    <time_frame>monthly after two months of AET; up to 3 months</time_frame>
    <description>patient reported intentional or accidental forgot the medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire on patients experience with the patient-physician relationship</measure>
    <time_frame>month 6 or 7 after the start with AET</time_frame>
    <description>patient reported their experience of the follow-up consultation in a 5 point Likert scale questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire on change in patient-relative communication over a period of +/- 3 months</measure>
    <time_frame>month 3 and 6 or 7 after the start with AET</time_frame>
    <description>patient reported a change in the communication of patients with their relatives in a 5 point Likert scale questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>Monthly after two months of AET; up to 3 months</time_frame>
    <description>Subscales of FACT-ES combined with additional questions B5 and H18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire on the experience of the healthcare professional regarding the summary of PRO's</measure>
    <time_frame>month 6 or 7 after the start of AET</time_frame>
    <description>the experience of healthcare professionals with the consultation with a 5 point Likert scale questionnaire (1 = strongly disagree, and 5 = strongly agree). The maximum score is 25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-spend on Co'moon</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Logging of the time women spend on Co'moon</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Quality of Life</condition>
  <condition>Self Efficacy</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care:&#xD;
a short overview of the physician on adjuvant endocrine therapy&#xD;
a brochure on adjuvant endocrine therapy&#xD;
a voluntary group session on adjuvant endocrine therapy&#xD;
and a monthly questionnaire on the patient reported outcomes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care with the access of to the online tool Co'moon and a monthly questionnaire on patient reported outcomes.&#xD;
The outcome of the questionnaires are summarized for the physician to discuss during the follow-up consultation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Co'moon (online website to support women with AET)</intervention_name>
    <description>The tool contains three parts:&#xD;
e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,&#xD;
serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,&#xD;
a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.&#xD;
The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals .</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Class 1 medical device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria patients:&#xD;
&#xD;
          -  Women&#xD;
&#xD;
          -  Older than 18 years&#xD;
&#xD;
          -  Speaking, understanding and writing Dutch fluently&#xD;
&#xD;
          -  Mentally competent&#xD;
&#xD;
          -  Recently underwent a operation for breast cancer (invasive or in situ)&#xD;
&#xD;
          -  Takes AET for maximum two months&#xD;
&#xD;
          -  Consultation planned within 4-5 month&#xD;
&#xD;
          -  Home access of a computer with internet connection&#xD;
&#xD;
        Exclusion Criteria patients:&#xD;
&#xD;
          -  Different treatments regimes (e.g. adjuvant trial or a combination with&#xD;
             cycline-dependent kinase (CDK) 4/6-inhibitors)&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
        Inclusion Criteria health care professionals:&#xD;
&#xD;
          -  Contact with patient(s) included in the trial&#xD;
&#xD;
        Exclusion Criteria health care professionals:&#xD;
&#xD;
          -  Included in panels&#xD;
&#xD;
          -  Member of the research team&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ines Nevelsteen, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ines Nevelsteen, Phd</last_name>
    <phone>016 34 68 31</phone>
    <email>ines.nevelsteen@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rani Vanhoudt, Msc</last_name>
    <phone>016 34 69 23</phone>
    <email>rani.vanhoudt@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Nevelsteen, Phd</last_name>
      <phone>016 34 68 31</phone>
      <email>ines.nevelsteen@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Rani Vanhoudt, Msc</last_name>
      <phone>016 34 69 23</phone>
      <email>rani.vanhoudt@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Ines Nevelsteen Nevelsteen, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rani Vanhoudt, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

